BIOD351 Module 9 FINAL TEST READINESS EXAM Q & S ‚ ©2026/2027

BIOD351
Module 9
FINAL TEST READINESS EXAM
Q & S
©2026/2027
1. Multiple Choice: What is the primary mechanism of action
for monoclonal antibodies used in cancer therapy?
 a) Blockade of cell division
 b) Targeted delivery of cytotoxic agents
 c) Induction of immune-mediated cell death
 d) Inhibition of signal transduction pathways
 Correct Answer: c) Induction of immune-mediated cell
death
2. Fill-in-the-Blank: The process by which a cell absorbs a
drug or chemical through its cell membrane is known as
__________.
 Correct Answer: Endocytosis
3. True/False: Biosimilars are identical to their reference
biologic drugs in terms of efficacy and safety.
 Correct Answer: False
4. Multiple Response: Which of the following are considered
targeted therapies? (Select all that apply)
 a) Chemotherapy
 b) Hormone therapy
 c) Immunotherapy
 d) Radiotherapy
  : b) Hormone therapy, c) Immunotherapy
5. Multiple Choice: What is the role of pharmacogenomics
in specialty medication?
 a) To determine the standard dosage for all patients
 b) To predict a patient's response to a drug based on their